ACIU biotech catalysts & pipeline

AC IMMUNE SA · Data as of 2026-10-25

Upcoming catalysts

ACI-19764 — Initial data

Late 2026

Dosing of patients with cardiovascular risk factors has commenced in a Phase 1 b portion of the trial with initial results on inhibition of inflammation as measured by hsCRP reduction expected around year end ;

Source filing

ACI-19764 — Full data

H1 2027

Full results from the Phase 1/1b trial are expected in H1 2027

Source filing

ACI-7104 — FDA meeting

early 2027

Discussions with FDA regarding future development path planned for early 2027

Source filing

ACI-7104 — FDA meeting

2027

The final design of Part 2 is being consolidated and will be submitted to the FDA for review, with meetings expected early in 2027.

Source filing

Explore the free biotech catalyst calendar